15 Jun 2011 11:30
15 June 2011
LSE: VER
Vernalis Results of Annual General Meeting
Resolutions
Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.
All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.
Resolution | For (including discretionary votes)* | Against* | Withheld | ||
Ordinary Resolutions (requires 50% majority) | |||||
1. That the audited accounts and related reports of the Directors and auditors for the year ended 31 December 2010 be received | 82,539,606 | (99.99 %) | 1,128 | (0.01%) | 235 |
2. That the remuneration report contained within the report and accounts for the year ended 31 December 2010 be approved | 82,529,051 | (99.99 %) | 10,295 | (0.01%) | 1,623 |
3. That PricewaterhouseCoopers LLP be reappointed auditors and the Directors be authorised to determine their remuneration | 82,536,498 | (99.99 %) | 2,904 | (0.01%) | 1,567 |
4. That the Directors be authorised to allot shares | 82,533,397 | (99.99 %) | 5,950 | (0.01%) | 1,622 |
Special Resolutions (requires 75% majority) | |||||
5. That the Directors be authorised to disapply pre-emption rights | 82,534,504 | (99.99 %) | 5,501 | (0.01%) | 964 |
6. That General Meetings, other than Annual General Meetings, may be called on not less than 14 clear days' notice | 82,535,366 | (99.99 %) | 4,963 | (0.01%) | 640 |
*NB: Percentage of votes cast excludes withheld votes
The Company confirms that copies of all resolutions passed at the Annual General Meeting held earlier today, Wednesday 15 June 2011, will be submitted to the National Storage Mechanism (NSM) at www.hemscott.com/nsm.co and will shortly be available for viewing
- ends -
Enquiries:
Vernalis | +44 (0) 118 989 9360 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles Justine McIlroy
| |
Taylor Rafferty | +44 (0) 20 7614 2900 |
Rob Newman Faisal Kanth |
About Vernalis:
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.
For further information about Vernalis, please visit www.vernalis.com.